Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour

Ferdinando C M Cananzi, Ajay P. Belgaumkar, Bruno Lorenzi, Satvinder Mudan

Research output: Contribution to journalArticle

Abstract

Introduction: After the introduction of tyrosine kinase inhibitors (TKIs), the role of surgical resection in treating liver metastasis from gastrointestinal stromal tumour (GIST) is unclear. In this study, we evaluated the outcome of patients treated with TKIs followed by surgery for metastatic GIST. Methods: Eleven patients underwent liver resection after downsizing TKIs therapy for metastatic GIST from 2006 until 2010 were reviewed. Results: One and two-year overall survival rates were 80.8 and 70.7%. All patients with an initially resectable tumour were still alive without recurrence. Patients operated on clinical response had a better outcome (1- and 2-year overall survival (OS) rate 100%) than those operated on disease progression (1- and 2-year OS rates 60 and 40%; P=0.043). No deaths were observed among patients who achieved an R0 resection (R0 versus R1/R2, P=0.001). Discussion: R0 resection and clinical response to TKI are predictor of survival. Surgical resection should be performed as soon as feasible in responding patients. In poor responders, surgery may not add any survival benefit, except in localized progressive disease. In resectable metastatic liver disease, preoperative TKIs or upfront surgery followed by adjuvant therapy could be considered. Larger studies are needed to determine the optimum approach in patients with metastatic GIST.

Original languageEnglish
Pages (from-to)E1-E8
JournalANZ Journal of Surgery
Volume84
Issue number12
DOIs
Publication statusPublished - 2014

    Fingerprint

Keywords

  • GIST
  • Imatinib
  • Liver metastases
  • Liver resection
  • Preoperative therapy

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this